If you are searching for “what is spravato esketamine,” you are looking for a clear explanation. Spravato is a prescription nasal spray containing esketamine, the S-enantiomer of ketamine. It is not generic ketamine, and it is not an at-home treatment. For eligible adults with treatment-resistant depression, Impireum describes Spravato as an in-office treatment used alongside an oral antidepressant under an approved clinical protocol, with clinician evaluation required.
Call Impireum at (877) 631-0010 to ask about an evaluation. Please use an approved secure channel for personal health information.
Understanding treatment-resistant depression options starts with knowing how Spravato differs from other depression treatments. The sections below explain what the medication is, who may qualify, and why each visit takes place under direct medical supervision.
What Is Spravato Esketamine?
Spravato is the brand name for prescription intranasal esketamine, a medication used in a supervised healthcare setting for certain adults with treatment-resistant depression. If you have searched for “what is spravato esketamine,” the short answer is that Spravato is a specific nasal-spray medicine, not a general term for every form of ketamine treatment. The current FDA prescribing information provides the official medication and safety details. You can also review Impireum’s Spravato treatment information for service-specific context.
Esketamine is the S-enantiomer, or one molecular form, of racemic ketamine. Although the medicines are chemically related, Spravato is not the same as generic ketamine, and its administration follows a defined prescription and monitoring process. It is not an at-home treatment. A patient uses the nasal spray under the supervision of a healthcare provider in an appropriate certified setting.
How Spravato fits into depression care
The FDA labeling includes treatment-resistant depression in adults among its indications. That label information does not determine whether the treatment is appropriate for a particular person or describe every clinic’s protocol. Impireum’s approved protocol uses Spravato alongside an oral antidepressant, rather than as monotherapy. In other words, this article should not be read as suggesting that Impireum offers Spravato alone or that a broader label authorizes monotherapy through the practice.
Eligibility is considered through a clinical evaluation. The clinician reviews a person’s diagnosis, treatment history, current medications, medical factors, and safety considerations before determining whether an evaluation for Spravato is appropriate. Impireum’s published guidance discusses the treatment for adults with treatment-resistant depression who have not responded adequately to at least two prior antidepressant trials, while individual eligibility still requires professional assessment.
Because Spravato is administered through the restricted Spravato Risk Evaluation and Mitigation Strategy program, treatment involves more than receiving a prescription and taking a spray home. The certified setting, observation period, and follow-up process are part of responsible care and are explained in the treatment sections that follow.
How Is Spravato Different from Traditional Antidepressants?
Traditional antidepressants are commonly taken by mouth on a regular schedule at home, while Spravato is a prescription nasal spray administered in a certified healthcare setting under provider supervision. At Impireum, the approved protocol uses Spravato alongside an oral antidepressant, rather than presenting it as a standalone medication option. The practical difference is the care setting and monitoring required, not a promise that one approach will work better for every person.
| Consideration | Spravato visits | Traditional oral antidepressants |
|---|---|---|
| How it is taken | The patient uses the nasal spray under the supervision of a healthcare provider. | The patient takes the medication by mouth according to the prescribing clinician’s directions. |
| Where it is provided | In a healthcare setting certified through the Spravato Risk Evaluation and Mitigation Strategy (REMS) program. | Typically taken at home, with prescribing and follow-up appointments arranged with a clinician. |
| Monitoring | Blood pressure is assessed before and after administration, and the provider monitors the patient for at least two hours. | Monitoring occurs through clinical follow-up, medication reviews, and communication about symptoms or side effects. |
| Care plan at Impireum | Used with an oral antidepressant under the clinic’s approved protocol after a clinician evaluates eligibility. | May be prescribed as part of an individualized medication plan, based on clinical evaluation and follow-up. |
Because Spravato requires observation, patients should plan for time at the clinic and follow the provider’s instructions about leaving safely. It is not an at-home treatment. The FDA label states that Spravato is available only through the restricted REMS program and only at certified healthcare settings. These requirements help explain why the treatment pathway differs from picking up an oral prescription and taking it independently.
Whether this type of supervised care is appropriate depends on an individual evaluation, medical history, current treatment plan, and applicable safety considerations. A clinician can explain how the options fit together without assuming that either treatment is right for everyone. For broader context, review Impireum’s treatment-resistant depression options.
Who Qualifies for Spravato Treatment?
Spravato is considered for adults with treatment-resistant depression, but a diagnosis or past treatment history does not automatically mean someone qualifies. The FDA labeling identifies treatment-resistant depression as an adult indication, while Impireum’s published guidance describes its protocol for patients who have not responded adequately to at least two prior antidepressant trials. This threshold is an important starting point, not a guarantee of treatment access or suitability.
A qualified clinician must review each person’s history before recommending care. That review may include prior diagnoses, medications and treatment response, current symptoms, medical conditions, mental health history, and other safety considerations. The clinician also needs to determine whether Spravato, used alongside an oral antidepressant under Impireum’s approved protocol, fits the person’s broader treatment plan. Spravato should not be presented as a self-selected replacement for a careful psychiatric evaluation.
The evaluation also considers practical readiness. Spravato is administered under healthcare-provider supervision in a certified setting through the restricted SPRAVATO REMS program. Patients must be able to attend supervised visits and remain available for post-administration monitoring. The FDA medication guide states that a healthcare provider monitors patients for at least two hours and decides when they are ready to leave. These requirements mean that an at-home or unsupervised arrangement is not an alternative.
Spravato is not approved for children, so this discussion is focused on adults. Other factors may affect eligibility, including safety concerns, medication interactions, blood-pressure considerations, and the clinician’s assessment of the current level of care needed. If symptoms indicate a need for a higher level of support, the clinician will address that directly rather than assuming Spravato is appropriate.
Impireum’s team can discuss whether an evaluation may be appropriate for an adult who has experienced persistent symptoms despite prior treatment. Learn more about treatment-resistant depression options, and confirm current availability, clinical eligibility, and coverage with the practice before making plans.
What Does a Spravato Treatment Session Involve?
A Spravato visit is structured around supervised administration and observation, not a quick prescription pickup. The medication is available only through the restricted Spravato Risk Evaluation and Mitigation Strategy (REMS) program, and it must be given in a certified healthcare setting. The FDA prescribing information describes the required monitoring and safety framework.
- Evaluation and check-in. A qualified provider confirms that the visit is appropriate, reviews your current health information and medications, and checks for factors that may affect safe administration. Blood pressure is assessed before treatment. Eligibility and clinical decisions are individualized, so the visit may include questions about symptoms, prior treatment, and your overall care plan.
- Provider-directed nasal spray. You use the nasal spray yourself while a healthcare provider supervises you in the certified setting. This is not an at-home treatment. Follow the provider’s instructions for using the device, and ask questions before administration if any part of the process is unclear.
- Direct observation and monitoring. A healthcare provider checks you during and after administration. Monitoring includes attention to your level of alertness, how you are feeling, and blood pressure after treatment. The FDA states that patients must be monitored for at least two hours after taking Spravato. The experience can vary, and the team can respond if concerns arise.
- Discharge decision. You do not leave simply because a set amount of time has passed. The provider decides when you are ready to leave the healthcare setting after the required observation period and clinical checks. If you feel unwell or have questions during monitoring, tell the care team promptly.
- Transportation and next-day precautions. Arrange transportation home in advance. Do not plan to drive yourself after the visit, and follow the provider’s instructions about driving, operating machinery, and other safety-sensitive activities through the next day. Your clinic will explain any additional precautions that apply to your circumstances.
Impireum’s published guidance describes an in-office, REMS-certified program with two-hour monitoring. The exact check-in process and clinical instructions can vary, so ask the care team what to expect when discussing whether this treatment may fit your needs. Read the FDA prescribing information for Spravato for the official safety and administration requirements.
What Are the Side Effects of Spravato?
Spravato can cause effects that are noticeable during or after a supervised treatment session. Possible risks include sedation, dissociation, dizziness, nausea, and a temporary increase in blood pressure. The FDA medication information also warns about respiratory depression and the potential for abuse or misuse. These risks are reasons Spravato is administered in a qualified healthcare setting rather than used independently at home.
What patients may notice
Sedation can make you feel unusually sleepy or less alert. Dissociation may involve feeling detached from your surroundings, your body, or your usual sense of time. Dizziness and nausea can also occur. A temporary rise in blood pressure may last for about four hours after a dose, which is why blood pressure is assessed before and after administration. The FDA prescribing information lists sedation, dissociation, respiratory depression, and blood-pressure changes among the safety concerns that require clinical attention. Read the FDA prescribing information for the complete safety details.
Why monitoring matters
Spravato is available only through the restricted Spravato Risk Evaluation and Mitigation Strategy (REMS) program and may be given only at a certified healthcare setting. A provider checks you during and after use, monitors you for at least two hours, and decides when you are ready to leave. This observation helps the care team respond to concerning symptoms and review whether the treatment remains appropriate for you.
Because Spravato is a Schedule III controlled substance, the FDA medication guide identifies a risk of abuse and misuse that may lead to physical or psychological dependence. Respiratory depression is another serious potential risk, particularly when other sedating substances or medications may be involved. Your clinician should review your health history, current medications, and individual risk factors before treatment. Do not assume that a symptom is harmless or that Spravato is appropriate based on general information alone. Discuss questions and concerns with the qualified clinician overseeing your evaluation and care.
Does Insurance Cover Spravato?
Insurance coverage for Spravato is plan-specific. A health plan may consider factors such as the diagnosis, the prescribing clinician, the treatment setting, network participation, and whether the medication and supervised administration are covered benefits. Coverage cannot be confirmed from the name of an insurance company alone, and approval for one patient does not establish coverage for another.
Before scheduling, ask the intake or benefits team to verify whether the clinic and relevant providers are in network. They can also clarify whether prior authorization is required, which clinical records the plan requests, and whether documentation of previous treatment is part of the review. Impireum’s published guidance describes Spravato as an option evaluated for adults who have not responded to at least two prior antidepressant trials. A clinician must still determine individual eligibility, and the plan may apply its own requirements.
Questions to ask about your benefits
- Is Spravato covered for the intended diagnosis under my specific plan?
- Is prior authorization required before the first visit or before each phase of treatment?
- What documentation of prior antidepressant treatment or other care is needed?
- Are the medication, administration, monitoring, and clinical visits billed separately?
- How do my deductible, copay, and coinsurance apply to these services?
- Are there network, site-of-care, referral, or benefit-year restrictions?
Benefits verification is not a guarantee of payment. Your insurer makes the final coverage determination, and benefits can change. Ask the plan for a reference number and request written details when possible. If you are contacting Impireum in Katy, Texas, use the approved intake channel for general questions and avoid sending protected health information through a public form or social media message.
How to Find Out If You Qualify at Impireum
Learning whether Spravato may be appropriate begins with a clinical evaluation, not a checklist or an online diagnosis. Impireum’s published guidance describes Spravato as a treatment considered for adults with treatment-resistant depression who have not responded adequately to at least two prior antidepressant trials. That history is an important starting point, but it does not determine eligibility by itself. A qualified clinician must review your symptoms, treatment history, current medications, health conditions, and safety considerations.
Impireum provides in-person care in Katy, Texas. During an initial conversation, ask whether the Spravato program is currently available for your situation. Also ask whether the treating provider and setting are authorized to provide it, and whether your state and service needs fit the practice’s current scope. Telehealth may be available for some behavioral-health services, but it does not mean Spravato can be administered remotely or at home. Spravato administration requires an appropriate supervised clinical setting.
You can review Spravato treatment information for the program’s general details, then contact the intake team to ask about an evaluation. Before scheduling, confirm whether your insurance plan, network, benefits, prior-authorization requirements, and the treatment setting are compatible. Coverage and eligibility are individual questions, so avoid assuming that a referral or past treatment automatically guarantees approval.
When asking about care, share only the information needed through an approved intake channel. Do not post diagnoses, medication lists, or other protected health information in a public form, comment, or social-media message. If you have urgent safety concerns or may need immediate help, seek emergency services rather than waiting for an outpatient evaluation.
Frequently Asked Questions
Is Spravato the same as ketamine?
Spravato is the brand name for prescription intranasal esketamine. Esketamine is the S-enantiomer of ketamine, but Spravato is a regulated medication with its own approved administration and monitoring requirements. The FDA label identifies it as a Schedule III controlled substance.
Who may qualify for Spravato treatment?
Impireum generally considers adults with treatment-resistant depression who have not responded adequately to at least two prior antidepressant trials. A qualified clinician must evaluate your diagnosis, treatment history, health conditions, current medications, and safety needs. Meeting a general threshold does not guarantee eligibility or treatment response.
Can I use Spravato at home?
No. Spravato is self-administered as a nasal spray only while you are under healthcare-provider supervision in a certified setting. It is not an at-home treatment. The provider monitors you during and after administration and determines when you are ready to leave.
How long does a Spravato visit take?
Plan for a supervised visit that includes administration and observation afterward. The FDA requires healthcare providers to monitor patients for at least two hours after use, and blood pressure is assessed before and after administration. Your provider gives individualized instructions about transportation, driving, and other safety precautions.
Does insurance cover Spravato?
Coverage varies by health plan, network, benefits, diagnosis, authorization requirements, and treatment setting. Impireum can help explain the verification process, but coverage and out-of-pocket responsibility must be confirmed for your specific plan. Ask about eligibility and benefits before scheduling, rather than relying on an assumed price or approval.
Ready to Ask About Spravato Next Steps?
A conversation with the Impireum team can help you understand whether an evaluation may be an appropriate next step and what information to bring to that discussion. Eligibility, availability, and coverage require individual review, and Spravato is provided under clinical supervision. To ask about an evaluation and next steps, call Impireum at (877) 631-0010.